GNRHR and endometrial cancer: Interestingly, the tissue-specific phase 3 oncology targets were aberrantly expressed in cancer (e.g., GNRHR is pituitary-specific in non-diseased state but ectopically expressed in endometrial cancers) or were targets of therapies accompanying cytostatic agents (e.g., hemoglobin as target of experimental drugs increasing tissue oxygenation to sensitize tumors to main therapy, NCT00083304).